Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

Trial Details

NCT ID
NCT06712316
Phase
PHASE2 / PHASE3
Sponsor
BioNTech SE
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Pumitamig
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Paclitaxel
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Concord, California, United States|37.97798,-122.03107
  • Clermont, Florida, United States|28.54944,-81.77285
  • Tampa, Florida, United States|27.94752,-82.45843
  • Cedar Rapids, Iowa, United States|42.00833,-91.64407

Key Eligibility Criteria

  • Have systemic treatment naive, histologically or cytologically confirmed diagnosis of Stage IIIB or IIIC (who are not amenable to curative surgery …
  • Have at least one measurable lesion as the targeted lesion based on RECIST v1.1. Lesions treated after prior local treatment (radiotherapy, ablatio…
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →